“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande, who left a16z's $4 billion biotech practice to start AI-native VZVC, says biology is shifting from discovery to engineering. He argues open, shared datasets, not walled-off ones, will let AI transform medicine, while clinical trials remain brutally expensive.